Updated results of the selective Bruton tyrosine kinase (BTK) inhibitor TG-1701, as monotherapy and in combination with ublituximab and umbralisib (U2) in patients (pts) with B-cell malignancies.

被引：1

作者：

Cheah, Chan

Jurczak, Wojciech

Lasica, Masa

Wickham, Nicholas W.

Wrobel, Tomasz

Walewski, Jan Andrzej

Yannakou, Costas K.

Cheung, Stanley

Lewis, Katharine L.

Dlugosz-Danecka, Monika

Giannopoulos, Krzysztof

Miskin, Hari P.

Tang, Jian-Ping

Normant, Emmanuel

O'Connor, Owen A.

Ricart, Alejandro Daniel

Tam, Constantine Si Lun

机构：

[1] Sir Charles Gairdner Hosp, Comprehens Canc Ctr, Nedlands, WA, Australia

[2] Maria Sklodowska Curie Natl Inst Oncol, Krakow, Poland

[3] St Vincents Hosp Sydney, Darlinghurst, NSW, Australia

[4] Ashford Canc Ctr Res, Adelaide, SA, Australia

[5] Wroclaw Med Univ, Dept Hematol, Wroclaw, Poland

[6] Maria Sklodowska Curie Canc Ctr, Warsaw, Poland

[7] Inst Oncol, Warsaw, Poland

[8] Epworth HealthCare, East Melbourne, Australia

[9] Ashford Canc Ctr Res, Adelaide, SA, Australia

[10] Sir Charles Gairdner Hosp, Nedlands, WA, Australia

[11] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland

[12] St Johns Canc Ctr, Hematol Dept, Lublin, Poland

[13] TG Therapeut Inc, New York, NY USA

[14] TG Therapeut, New York, NY USA

[15] Inst Onc Henry Moore, Buenos Aires, DF, Argentina

[16] St Vincents Hosp, Melbourne, Vic, Australia

[17] Univ Melbourne, Melbourne, Vic, Australia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.7525

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7525

引用

页数：3